This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2023.
Program Description
The rapid development and approval of antibody-based treatments, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has posed several challenges for oncology pharmacists. Considerations for the effective and safe administration and implementation of antibody-based regimens in the treatment and management of R/R DLBCL will be discussed. Expert panelists will outline approaches for oncology pharmacists to integrate these emerging therapies into clinical practice and overcome operational challenges to facilitate access to novel antibody-based therapies in early lines of therapy for patients with R/R DLBCL. This program is a continuation of “Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens,” and will build upon clinical data and topics presented.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 14, 2023
Expiration date: April 14, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore strategies for mitigating and monitoring drug-related toxicities of novel treatment modalities in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
- Plan for optimal, safe use of antibody-based regimens in R/R DLBCL through pharmacist-led development of guidelines and standard operating procedures
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
